Cargando…

Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma

Induction chemotherapy based on high-dose methotrexate is considered as the standard approach for newly diagnosed primary central nervous system lymphomas (PCNSLs). However, the best combination chemotherapeutic regimen remains unclear. This study aimed to determine the efficacy and toxicities of ri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Xianggui, Yu, Teng, Huang, Yurong, Jiang, Huawei, Xu, Xiaohua, Liang, Yun, Qian, Wenbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747713/ https://www.ncbi.nlm.nih.gov/pubmed/36513674 http://dx.doi.org/10.1038/s41598-022-24922-y

Ejemplares similares

P1145: PRELIMINARY RESULTS OF PENPULIMAB COMBINED WITH RMA(RITUXIMAB, METHOTREXATE, AND CYTARABINE) FOR NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Shen, Haorui, et al.
Publicado: (2023)

ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
por: Takezaki, Tatsuya, et al.
Publicado: (2020)

Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma
por: Zhao, Defeng, et al.
Publicado: (2014)

Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
por: Sun, Xuefei, et al.
Publicado: (2017)

PB2315: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZR OR ZRM REGIMEN (ZANUBRUTINIB, RITUXIMAB, METHOTREXATE)
por: Teng, Yue, et al.
Publicado: (2023)

Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience
por: Suleman, Adam, et al.
Publicado: (2022)

Advances in the treatment of newly diagnosed primary central nervous system lymphomas
por: Qian, Liren, et al.
Publicado: (2017)

The Role of Rituximab in Primary Central Nervous System Lymphoma
por: Bromberg, Jacoline E. C., et al.
Publicado: (2020)

Radiotherapy for newly diagnosed primary central nervous system lymphoma: role and perspective
por: Thomas, Alice, et al.
Publicado: (2023)

Improvement of outcomes of an escalated high‐dose methotrexate-based regimen for patients with newly diagnosed primary central nervous system lymphoma: a real-world cohort study
por: Li, Qing, et al.
Publicado: (2021)

P1223: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN（ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE)
por: Tang, Y.
Publicado: (2022)

The Efficacy and Safety of Cytarabine on Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis
por: Zheng, Xiaohong, et al.
Publicado: (2020)

High‐dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China
por: Chen, Cui, et al.
Publicado: (2019)

The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma
por: Van Dijck, Ruben, et al.
Publicado: (2021)

First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study
por: Zhong, Kaili, et al.
Publicado: (2023)

Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma
por: Wang, Yi-Xia, et al.
Publicado: (2020)

High‐dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma
por: Akiyama, Hiroki, et al.
Publicado: (2016)

Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma
por: Fujimoto, Kenji, et al.
Publicado: (2020)

Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma
por: Bernard, S., et al.
Publicado: (2021)

A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma
por: Villanueva, Gabriela, et al.
Publicado: (2023)

ML-14 LOW INVASIVE APPROACH FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA TREATMENT INVOLVING RITUXIMAB–METHOTREXATE + PROCARBAZINE + VINCRISTINE AND TRIPLE INTRATHECAL INJECTION
por: Ogawa, Takahiro, et al.
Publicado: (2019)

ML-08 Safety and efficacy of consolidation cytarabine for newly-diagnosed primary central nervous system lymphoma
por: Sasaki, Nobuyoshi, et al.
Publicado: (2020)

Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report
por: Beziat, Guillaume, et al.
Publicado: (2020)

Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma
por: Kuhlman, Justin J, et al.
Publicado: (2022)

High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis
por: Li, Yufeng, et al.
Publicado: (2023)

Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
por: Wu, Jingjing, et al.
Publicado: (2022)

Combination Therapy with Rituximab and Temozolomide for Recurrent and Refractory Primary Central Nervous System Lymphoma
por: Murakami, Mineko, et al.
Publicado: (2011)

Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
por: Fan, Ni, et al.
Publicado: (2017)

ML-16 First clinical experience of administration of Tirabrutinib for the patients with newly diagnosed primary central nervous system lymphoma
por: Onodera, Sho, et al.
Publicado: (2021)

Effect of Intravitreal Methotrexate and Rituximab on Interleukin-10 Levels in Aqueous Humor of Treated Eyes with Vitreoretinal Lymphoma
por: Raja, Harish, et al.
Publicado: (2013)

Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma
por: Lee, Bryan S., et al.
Publicado: (2014)

Successful rapid drug desensitization to methotrexate in a patient with primary central nervous system lymphoma
por: Song, Kyung Mee, et al.
Publicado: (2018)

Primary Central Nervous System T-cell Lymphoma as Methotrexate-associated Lymphoproliferative Disorders: Case Report
por: KAWANO, Hiroto, et al.
Publicado: (2021)

ML-04 The influence of surgical intervention for high-dose Methotrexate chemotherapy in the patients with primary central nervous system lymphoma
por: Okamoto, Michinari, et al.
Publicado: (2020)

Rituximab Monotherapy for Grade 2-3 Lymphomatoid Granulomatosis with Central Nervous System Involvement in a Patient Receiving Methotrexate for Rheumatoid Arthritis
por: Hosoi, Hiroki, et al.
Publicado: (2022)

Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma: Erratum
Publicado: (2014)

Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells
por: Takashima, Yasuo, et al.
Publicado: (2019)

Factors Influencing the Response to High Dose Methotrexate-based Vincristine and Procarbazine Combination Chemotherapy for Primary Central Nervous System Lymphoma
por: Sung, Kang Hyun, et al.
Publicado: (2011)

Urine volume to hydration volume ratio is associated with pharmacokinetics of high‐dose methotrexate in patients with primary central nervous system lymphoma
por: Isono, Tetsuichiro, et al.
Publicado: (2021)

Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy
por: Luo, Qian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mgv1qicaa6i956v73dq0v743qs